

HPMS E-Mail

Date: June 06, 2023

Subject: Medicare Advantage and Prescription Drug Programs: Part C and Part D
Explanation of Benefits, 60-Day Comment Period for Proposed Information
Collection

Sections 1852(k)(2)(C)(i) and 1860D-4(a)(4) of the Social Security Act require Medicare Advantage (MA) organizations and Medicare Prescription Drug Program (Part D) plan sponsors, respectively, to distribute a written explanation of benefits (EOB) to enrollees when benefits are provided to them under their plan. EOB requirements codified at 42 CFR §§ 422.111(k) and 423.128(e) ensure that MA and Part D enrollees receive consistent and timely information about costs associated with their medical claims.

On June 6, 2023, CMS posted a notice in the Federal Register (88 FR 37066) announcing the 60-day public comment period for the proposed information collection requirements associated with the EOBs. Proposed changes to this information collection include updates to the Part D EOB to comply with the Part D benefit redesign provisions in section 11201 of the Inflation Reduction Act of 2022.

CMS encourages interested parties to review the Federal Register notice for the proposed Medicare Advantage and Prescription Drug Programs - Part C and Part D CY 2025 Explanation of Benefits information collection (CMS-10453, OMB 0938-1228), which is published at: <https://www.federalregister.gov/documents/2023/06/06/2023-11996/agency-information-collection-activities-proposed-collection-comment-request>. Comments must be received by August 7, 2023, to be considered, and must be submitted as described in the Federal Register notice. The supporting statement and related documentation are available at: <https://www.cms.gov/regulations-and-guidance/legislation/paperworkreductionactof1995/practicing/1719218337/cms-10453>.